Robert J. Brooks
Arizona Oncology · 17 works · 409 citations · h-index 10
Top works
- Treatment of advanced breast cancer with mitomycin C combined with vinblastine or vindesine.
- Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine
- Hemoglobin casper: β 106 (G8) Leu→Pro
- Comparison of Menopausal Symptoms During the First Year of Adjuvant Therapy With Either Exemestane or Tamoxifen in Early Breast Cancer: Report of a Tamoxifen Exemestane Adjuvant Multicenter Trial Substudy
- Abstract S4-2: First Efficacy Results of a Randomized, Open-Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without Capecitabine, in High-Risk Early Breast Cancer
- Phase I trial of esorubicin (4'deoxydoxorubicin).
- Interaction of allopurinol with 6-mercaptopurine and azathioprine.
- A planned comparison of menopausal symptoms during the first year in 1,000 patients receiving either exemestane or tamoxifen in a double-blind adjuvant hormonal study
- Neurobehavioral and Psychosocial Functioning of Women Exposed to High Altitude in Mountaineering
- Effects of BCG on peripheral blood counts and drug tolerance of patients with non‐Hodgkin lymphoma receiving combination chemotherapy
- Use of dihydrofolate reductase from bovine liver, rather than from L. casei, for determining methotrexate.
- The effect of tamoxifen (T) or exemestane (E) on bone mineral density (BMD) after 1 year of adjuvant treatment of postmenopausal women with early breast cancer
- Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC) → docetaxel (T) with or without capecitabine (X) in high-risk early breast cancer: Exploratory Ki-67 analyses.
- Current Results of the University of Arizona Adjuvant Breast Cancer Trials (1974–1984)
- Adjuvant chemotherapy of axillary node-negative carcinoma of the breast using doxorubicin and cyclophosphamide.
- Neurobehavioral and psychosocial functioning in women exposed to high altitude in mountaineering
- Adjuvant capecitabine for invasive lobular/mixed early breast cancer (EBC): USON 01062 exploratory analyses.